207 related articles for article (PubMed ID: 10503734)
1. Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?
Lissoni P; Brivio F; Viviani S; Fumagalli L
J Biol Regul Homeost Agents; 1999; 13(2):110-4. PubMed ID: 10503734
[TBL] [Abstract][Full Text] [Related]
2. Melatonin as a new possible anti-inflammatory agent.
Lissoni P; Rovelli F; Meregalli S; Fumagalli L; Musco F; Brivio F; Brivio O; Esposti G
J Biol Regul Homeost Agents; 1997; 11(4):157-9. PubMed ID: 9582617
[TBL] [Abstract][Full Text] [Related]
3. Correlation between pretreatment serum levels of neopterin and response to interleukin-2 immunotherapy in cancer patients.
Lissoni P; Barni S; Ardizzoia A; Scardino E; Tancini G; Viganò MG
J Biol Regul Homeost Agents; 1995; 9(1):21-3. PubMed ID: 8553904
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of erythrosedimentation rate in cancer in relation to cytokine production: correlation with high IL-6 and low IL-2 blood concentrations.
Lissoni P; Brivio F; Pittalis S; Rovelli F; Rescaldani R; Perego MS; Grassi MG; Barni S; Tancini G; Majorca F; Fumagalli L
J Biol Regul Homeost Agents; 1996; 10(2-3):60-2. PubMed ID: 9250887
[TBL] [Abstract][Full Text] [Related]
5. Relation of pro- and anti-inflammatory cytokines and the production of nitric oxide in patients receiving high-dose immunotherapy with interleukin-2.
Locker GJ; Kofler J; Stoiser B; Wilfing A; Wenzel C; Wögerbauer M; Steger GG; Zielinski CC; Mader R; Burgmann H
Eur Cytokine Netw; 2000 Sep; 11(3):391-6. PubMed ID: 11022123
[TBL] [Abstract][Full Text] [Related]
6. Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy.
Lissoni P; Mengo S; Mandalà M; Mauri E; Brivio F; Rovelli F; Confalonieri G; Longarini R; Bonfante A; Folli D; Meregalli S; Barni S; Tancini G; Giani L
J Biol Regul Homeost Agents; 1998; 12(1-2):38-41. PubMed ID: 9677534
[TBL] [Abstract][Full Text] [Related]
7. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients.
Moroni M; Porta C; De Amici M; Quaglini S; Cattabiani MA; Buzio C
Haematologica; 2000 Mar; 85(3):298-303. PubMed ID: 10702820
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment serum markers and lymphocyte response to interleukin-2 therapy.
Fumagalli L; Lissoni P; Di Felice G; Meregalli S; Valsuani G; Mengo S; Rovelli F
Br J Cancer; 1999 May; 80(3-4):407-11. PubMed ID: 10408846
[TBL] [Abstract][Full Text] [Related]
9. Serum concentrations of sIL-2R, IL-6, TGF-beta1, neopterin, and zinc in chronic hepatitis C patients treated with interferon-alpha.
Grüngreiff K; Reinhold D; Ansorge S
Cytokine; 1999 Dec; 11(12):1076-80. PubMed ID: 10623433
[TBL] [Abstract][Full Text] [Related]
10. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
11. Soluble immunological parameters and early prognosis of renal cell cancer patients.
Kallio JP; Tammela TL; Marttinen AT; Kellokumpu-Lehtinen PL
J Exp Clin Cancer Res; 2001 Dec; 20(4):523-8. PubMed ID: 11876546
[TBL] [Abstract][Full Text] [Related]
12. [The value of measuring the serum level of soluble interleukin-2 receptors in lung cancer patients].
Siemińska A
Pol Merkur Lekarski; 2004 Feb; 16(92):188-90. PubMed ID: 15176308
[TBL] [Abstract][Full Text] [Related]
13. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
14. Renal cell carcinoma-associated immune impairment that may interfere with the response to cytokine therapy.
Lauerová L; Dusek L; Simícková M; Rovný F; Spurný V; Rovný A; Slampa P; Zaloudík J; Rejthar A; Wotke J; Kovarík J
Neoplasma; 1999; 46(3):141-9. PubMed ID: 10613588
[TBL] [Abstract][Full Text] [Related]
15. Serum sIL-2r, IL-6, IL-10 and TNF-alpha level in familial Mediterranean fever patients.
Baykal Y; Saglam K; Yilmaz MI; Taslipinar A; Akinci SB; Inal A
Clin Rheumatol; 2003 May; 22(2):99-101. PubMed ID: 12740672
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C.
Kitaoka S; Shiota G; Kawasaki H
Hepatogastroenterology; 2003; 50(53):1569-74. PubMed ID: 14571788
[TBL] [Abstract][Full Text] [Related]
17. Cytokine profile of Armenian patients with Familial Mediterranean fever.
Manukyan GP; Ghazaryan KA; Ktsoyan ZhA; Tatyan MV; Khachatryan ZA; Hakobyan GS; Mkrtchyan VA; Kelly D; Coutts A; Aminov RI
Clin Biochem; 2008 Jul; 41(10-11):920-2. PubMed ID: 18440310
[TBL] [Abstract][Full Text] [Related]
18. Molecular immunological approaches to biotherapy of human cancers--a review, hypothesis and implications.
Becker Y
Anticancer Res; 2006; 26(2A):1113-34. PubMed ID: 16619514
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.
Donskov F
Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677
[TBL] [Abstract][Full Text] [Related]
20. [Cytokines and soluble cytokine receptors in the perioperative period].
Maruna P; Gürlich R; Frasko R; Chachkhiani I; Marunová M; Owen K; Pesková M
Sb Lek; 2002; 103(2):273-82. PubMed ID: 12688152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
